Immunobiology Laboratory, Room 3602, Building 149, Massachusetts General Hospital and Harvard Medical School, 13th Street, Charlestown, Massachusetts 02129, USA.
Nat Rev Drug Discov. 2010 Jun;9(6):482-93. doi: 10.1038/nrd3030. Epub 2010 May 21.
Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies.
尽管自身免疫性疾病的药物研发已经取得了进展，但许多当前的治疗方法都受到不良反应的影响，而且除了病理性细胞之外，还经常破坏或失活健康细胞。目前还没有发现能够消除导致自身细胞攻击的罕见自身反应性免疫细胞的靶向自身免疫疗法。本文综述提出了一种新的新兴方法，旨在通过特异性激活肿瘤坏死因子受体 2（TNFR2）选择性地破坏自身反应性免疫细胞，TNFR2 存在于自身反应性和正常 T 淋巴细胞上，具有避免或减少现有治疗方法观察到的毒性的潜力。
